ASCEND Data Put InterMune’s Pirfenidone On Top
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.